製薬における精密医療と個別化医療 - テーマ別インテリジェンス

精密医療と個別化医療は、すでに疾患治療のパラダイムと医療の規定を再構築し始めています。患者の転帰の改善、QOLの向上、根治療法による疾病管理にかかる金銭的・時間的支出の削減、反応的ケアから予防的ケアへのシフトなどが、この分野における研究開発への投資を促進しています。

医療産業のデジタルトランスフォーメーションは、精密医療や個別化医療に向けた新しい診断法や治療法の開発を促進しています。例えば、次世代シーケンシング（NGS）によるバイオマーカー検査の進歩は患者の選択を改善し、ビッグデータセットの傾向を特定するAIの活用は創薬から商品化までの時間を加速し、ロボティクス、クラウド、IoTなどのインダストリー4.0技術の活用は細胞治療や遺伝子治療などの複雑な医薬品の製造の品質と効率を向上させています。

マクロ経済が乱高下する中、各国政府は市場参入を拡大するために薬価引き下げを模索する一方、医薬品の開発者は薬価引き下げがイノベーションを阻害すると主張しています。細胞治療や遺伝子治療のような医薬品には、従来の償還へのアプローチは機能せず、新たなモデルの採用のみが、市場参入と収益性にともに役立つ見込みです。

当レポートでは、製薬における精密医療と個別化医療について調査分析し、それらに影響を与える医療、マクロ経済、技術、規制の動向についての情報を提供しています。

目次

図のリスト

表のリスト

• 参入企業
• テーマの概説
• 動向
• 産業分析
• バリューチェーン
• 企業
• 医薬品開発スコアカード
• 略語
• 参考文献
• 著者について
• 当社のテーマ別調査手法

Abstract

Precision and personalized medicine has already begun to reshape disease treatment paradigms and the provision of healthcare. Improved patient outcomes, increased quality of life, reduced financial and time expenditure of disease management with curative therapies, and a shift from reactive to proactive care are all driving investment in R&D in this space.

The digital transformation of the healthcare industry is driving the development of new diagnostics and therapeutics for precision and personalized medicine. For example, advances in biomarker testing with next-generation sequencing (NGS) are improving patient selection, use of artificial intelligence (AI) in identifying trends in big datasets is accelerating the time from drug discovery to commercialization, and the use of Industry 4.0 technologies, such as robotics, cloud, and the Internet of Things (IoT), is improving the quality and efficiency of manufacturing complex drugs such as cell and gene therapies.

Drug pricing and reimbursement will continue to be the greatest challenge to the adoption of precision and personalized medicines, as governments look to reduce drug prices to increase market access during a time of macroeconomic turbulence, while drug developers argue that price drops stifle innovation. Traditional approaches to reimbursement do not work for drugs such as cell and gene therapies, and only the adoption of novel models will help to balance market access with profitability.

Key Highlights

• This report consolidates GlobalData's latest thinking and forecasts around how the healthcare, macroeconomic, technology, and regulatory trends will impact the precision and personalized medicine space, as well as providing insights into the leading players and future disruptors across the value chain, and providing insights into key drugs and markets from GlobalData's Pharma Intelligence Center
• The report is designed to provide strategic planners, competitive intelligence professionals and key stakeholders in the pharmaceutical industry a clear view of the opportunities and risks over the foreseeable future for precision and personalized medicines.

Scope

• A focused chapter on the key healthcare, technology, macroeconomic, and regulatory trends impacting precision and personalized medicine, and a review of the ways in which these trends will accelerate or hinder precision and personalized medicine.
• Industry analysis and market forecast for different therapies within precision and personalized medicine up to 2029.
• Case studies providing in-depth insight into some of the most recent and most influential developments in precision and personalized medicine, from recently approved gene therapies to new AI platforms to accelerate the development of new personalized drugs.
• Review of leaders and disruptors across the precision and personalized medicine value chain, covering diagnostics, therapeutics, and services.
• Thematic scorecard for drug development ranking companies on their investment in the top ten themes impacting the industry, one of which being precision and personalized medicine.

Reasons to Buy

• Understand the key trends accelerating or hindering the precision and personalized medicine space.
• See market forecasts for different therapies within precision and personalized medicine up to 2029.
• Understand recent and influential developments in precision and personalized medicine.
• Review of leaders and disruptors across the precision and personalized medicine value chain.

Table of Contents

Table of Contents

List of Figures

List of Tables

• Players
• Thematic Briefing
• Trends
• Industry Analysis
• Value Chain
• Companies
• Drug Development Scorecard
• Abbreviations
• Further Reading
• About the Authors
• Our Thematic Research Methodology